Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Memphasys Ltd ( (AU:MEM) ) just unveiled an update.
Memphasys has secured a key institutional win in the MENA region, with Qatar’s largest IVF provider, Hamad Medical Corporation, commencing commercial in-clinic use of the Felix™ system and placing ongoing orders for approximately 100 cartridges per month, supporting around 1,500 IVF cycles annually. This anchor customer, enabled by Felix™’s CE Mark approval, accounts for nearly half of distributor ITL’s minimum annual cartridge commitment and validates Memphasys’ direct go-to-market strategy in partnership with ITL, while a separate follow-on order for 200 cartridges from ITL for clinics beyond Qatar and late-stage negotiations across five additional countries underscore growing regional demand and the potential for meaningful recurring revenue, particularly in priority market Egypt and across more than 350 IVF clinics in MENA.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
More about Memphasys Ltd
Memphasys Limited is an Australian fertility-focused medical technology company that has developed the Felix™ system, a device and cartridge platform for improving sperm preparation in assisted reproductive technology (ART) and IVF procedures. The company is targeting fertility clinics globally, with a particular commercial focus on high-growth markets in the Middle East and North Africa (MENA), where IVF demand is expanding and individual clinics can generate substantial recurring revenue from Felix™ cartridge usage.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$13.44M
For a thorough assessment of MEM stock, go to TipRanks’ Stock Analysis page.